• Budesonide in Airway Inflammation Models: Protocols & Insigh

  2026-05-14

  Budesonide stands out as a high-impact anti-inflammatory corticosteroid for airway and respiratory disease research, enabling reproducible cell-based and permeability assays. This guide details advanced experimental workflows, critical protocol settings, and troubleshooting strategies—drawing on the latest biomimetic permeability modeling and APExBIO’s high-purity supply.

• Chloroquine: Technical Guide for Autophagy and Malaria Resea

  2026-05-13

  Chloroquine (SKU BA1002) addresses research needs in autophagy, malaria, and autoimmune disease modeling by precisely inhibiting lysosomal function and modulating key immune pathways. This guide covers actionable protocol parameters, quality control, and troubleshooting to ensure robust results. Its use should be restricted to applications with clear mechanistic rationale and established dosing guidance.

• (-)-Arctigenin as a MEK1 Inhibitor: Protocols & TME Innovati

  2026-05-13

  Leverage (-)-Arctigenin's nanomolar MEK1 inhibition and NF-κB pathway modulation for reproducible, high-impact tumor microenvironment research. Discover workflow enhancements, troubleshooting strategies, and translational insights rooted in recent breast cancer metastasis findings.

• Dual-Action p38α Inhibitors Accelerate Dephosphorylation Mec

  2026-05-12

  This study uncovers how certain p38α MAP kinase inhibitors not only block kinase activity but also accelerate phosphatase-mediated dephosphorylation. Structural and biochemical analyses reveal a conformational mechanism, informing future design of more specific and potent anti-inflammatory agents.

• Organic Cation Transporters and Xenobiotic Removal in Aedes

  2026-05-12

  Kennel and Rouhier (2025) investigated how Aedes aegypti mosquitoes respond to exposure to synthetic dyes, focusing on the physiological role and gene expression of putative organic cation transporters (OCTs/OCTNs). Their findings reveal that xenobiotic molecular structure, rather than transporter gene regulation, strongly influences excretion and toxicity, highlighting new molecular targets for mosquito control.

• Tapuy Lees Attenuate Neurodegeneration in C. elegans Disease

  2026-05-11

  Remucal et al. demonstrate that Tapuy lees, a by-product of traditional Filipino rice wine, significantly reduce amyloid-β toxicity and dopaminergic neurodegeneration in C. elegans models of Alzheimer’s and Parkinson’s diseases. The study highlights the superior antioxidant and neuroprotective properties of Tapuy lees over the wine itself, suggesting a novel direction for food-derived neurotherapeutics.

• Xenobiotic Transporter Response to Olsalazine in Aedes aegyp

  2026-05-11

  Kennel and Rouhier (2025) provide new insight into how Aedes aegypti mosquitoes handle synthetic xenobiotics such as Olsalazine Sodium and alizarin dyes. The study’s molecular and physiological findings inform potential strategies for vector control by characterizing the impact of xenobiotic structure on excretion, mortality, and transporter gene expression.

• Nonivamide (Capsaicin Analog): Applied TRPV1 Agonist Workflo

  2026-05-10

  Nonivamide, a selective TRPV1 agonist, is redefining cancer and neuroimmune assay design by enabling robust, reproducible apoptosis induction and inflammation modulation. This article translates recent mechanistic discoveries and experimental protocols into actionable guidance for leveraging Nonivamide in advanced in vitro and in vivo research.

• Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis

  2026-05-09

  This study introduces a prognostic signature based on ferroptosis-related genes for hepatocellular carcinoma (HCC) and identifies atorvastatin as a candidate therapeutic agent. The findings provide both a predictive biomarker model and experimental validation of an HMG-CoA reductase inhibitor as a ferroptosis inducer in HCC.

• Macrophage EV miR-660 Drives Breast Cancer via KLHL21/NF-κB

  2026-05-08

  This study reveals that tumor-associated macrophage-derived extracellular vesicles containing microRNA-660 enhance breast cancer metastasis by targeting KLHL21 and activating NF-κB p65 signaling. These insights clarify a key route for immune-mediated tumor progression and highlight potential molecular intervention points.

• Berberrubine Chloride: Applied Cancer & Metabolic Research W

  2026-05-08

  Berberrubine chloride offers researchers a multi-target tool for probing cancer, inflammation, and metabolic disorders. Discover evidence-based protocols, troubleshooting expertise, and cross-domain assay workflows that maximize the translational impact of this potent, DMSO-soluble alkaloid.

• I-BET-762 BET Inhibitor: Workflow Optimization in Cancer and

  2026-05-07

  I-BET-762, a highly selective BET inhibitor from APExBIO, streamlines both epigenetic and ferroptosis workflows in translational research. This article delivers evidence-driven guidance on protocol optimization, troubleshooting, and leveraging I-BET-762 for advanced anti-inflammatory and oncology models.

• STAMBPL1/TRIM21 Axis Regulates Immune Evasion in KIRC via AX

  2026-05-07

  This study delineates how STAMBPL1 modulates AXL stability by antagonizing TRIM21-mediated ubiquitination, driving mesenchymal transition and immune evasion in kidney renal clear cell carcinoma (KIRC). The discoveries highlight the potential of targeting the STAMBPL1/TRIM21/AXL pathway to counteract immunotherapy resistance and improve therapeutic outcomes.

• (-)-Epigallocatechin Gallate (EGCG): Mechanisms & Research U

  2026-05-06

  (-)-Epigallocatechin gallate (EGCG) is a major green tea catechin with robust antioxidant, antiangiogenic, and antiviral properties. EGCG modulates apoptosis, cell cycle, and signaling pathways, making it a versatile research tool for oncology and inflammation studies. This article provides evidence-backed guidance for EGCG's use, applications, and boundaries.

• Mubritinib–Human Serum Albumin Binding: Implications for Dru

  2026-05-06

  This article analyzes the molecular recognition mechanisms between the mitochondrial electron transport chain inhibitor mubritinib and human serum albumin (HSA). The study reveals moderate-affinity, site-specific binding and functional perturbation of HSA, highlighting key factors affecting drug pharmacokinetics and potential delivery strategies in cancer research.

15411 records 1/1028 page Next 12345 下5页 Last page